Development and evaluation of a SPR-based immunosensor for detection of anti-Trypanosoma cruzi antibodies in human serum

Luz, João Gabriel Guimarães; Souto, Dênio Emanuel Pires; Machado-Assis, Girley F.; Lana, Marta de; Kubota, Lauro T.; Luz, Rita C. S.; Damos, Flávio Santos; Martins, Helen Rodrigues

doi:10.1016/j.snb.2015.01.135

Cited by 21 publications

(20 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sensitivity indicates the total absence of false-negative results, while the specificity indicates a false-positive rate [ 28 ]); (iii) the need for dedicated laboratories to conduct the tests; and (iv) the requirement of long analysis times to obtain the results. IHA test results can be obtained in about two hours, whereas IIF results can be obtained after numerous steps in two hours and ELISA takes several hours to carry out, including prior sensitization of microplates with T. cruzi antigens for about 12 h [ 6 ]. Furthermore, all these tests have to be performed in centralized laboratories; some of them require sophisticated equipment and skilled technicians.…”

Section: Current Detection Technologies and Their Limitationsmentioning

confidence: 99%

“…In terms of the disease burden estimated by disability-adjusted life years (DALYs), CD figures as one of the most important parasitic vector-borne illnesses in the region of the Americas; DALYs for CD are more than five times higher than malaria and twice higher than dengue [ 3 ], and yet it is still absent in the agenda of the public health policies and practices of many endemic countries [ 4 , 5 ]. Furthermore, this disease ranks fourth in mortality and eighth in morbidity among global neglected tropical diseases [ 6 ], and it is estimated that between eight and eleven million people are infected, while 100 million are at risk of acquiring the disease. CD is caused by the parasitic presence of the Trypanosoma cruzi ( T. cruzi ) in the organism, which is mainly transmitted by contamination with the infected feces of blood-sucking triatomine vectors during a human blood meal.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Biosensors to Diagnose Chagas Disease: A Brief Review

Rocha-Gaso

Villarreal-Gómez

Beyssen

et al. 2017

Sensors

View full text Add to dashboard Cite

Chagas disease (CD), which mostly affects those living in deprived areas, has become one of Latin America’s main public health problems. Effective prevention of the disease requires early diagnosis, initiation of therapy, and regular blood monitoring of the infected individual. However, the majority of the Trypanosoma cruzi infections go undiagnosed because of mild symptoms, limited access to medical attention and to a high variability in the sensitivity and specificity of diagnostic tests. Consequently, more affordable and accessible detection technologies capable of providing early diagnosis and T. cruzi load measurements in settings where CD is most prevalent are needed to enable enhanced intervention strategies. This work analyzes the potential contribution of biosensing technologies, reviewing examples that have been tested and contrasted with traditional methods, both serological and parasitological (i.e., molecular detection by PCR), and discusses some emerging biosensing technologies that have been applied for this public health issue. Even if biosensing technologies still require further research efforts to develop portable systems, we arrive at the conclusion that biosensors could improve the accuracy of CD diagnosis and the follow-up of patients’ treatments in terms of the rapidity of results, small sample volume, high integration, ease of use, real-time and low cost detection when compared with current conventional technologies.

show abstract

Section: Current Detection Technologies and Their Limitationsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Biosensors to Diagnose Chagas Disease: A Brief Review

Rocha-Gaso

Villarreal-Gómez

Beyssen

et al. 2017

Sensors

View full text Add to dashboard Cite

show abstract

“…Because no standardized reference test is commercially available, the World Health Organization advises the use of two distinct techniques for CD diagnosis (7) and the Brazilian Health Ministry recommends 2 serological methods involving distinct antigen preparations, both of which must be performed concomitantly (6). Next-generation diagnostic platforms have improved the accuracy of CD diagnosis by using different T. cruzi-specific recombinant proteins in a variety of detection systems, such as chemiluminescence (8), surface plasmon resonance (9,10), and bead-based technologies, including cytometry bead arrays (11) and liquid microarrays (LMAs) (12).…”

mentioning

confidence: 99%

Performance Assessment of a Trypanosoma cruzi Chimeric Antigen in Multiplex Liquid Microarray Assays

et al. 2017

View full text Add to dashboard Cite

Diagnosing chronic Chagas disease (CD) requires antibody-antigen detection methods, which are traditionally based on enzymatic assay techniques whose performance depend on the type and quality of antigen used. Previously, 4 recombinant chimeric proteins from the Instituto de Biologia Molecular do Paraná (IBMP-8.1 to 8.4) comprising immuno-dominant regions of diverse antigens showed excellent diagnostic performance in enzyme-linked immunosorbent assays. Considering that next-generation platforms offer improved CD diagnostic accuracy with different-specific recombinant antigens, we assessed the performance of these chimeras in liquid microarrays (LMAs). The chimeric proteins were expressed in and purified by chromatography. Sera from 653 chagasic and 680 healthy individuals were used to assess the performance of these chimeras in detecting specific anti- antibodies. Accuracies ranged from 98.1 to 99.3%, and diagnostic odds ratio values were 3,548 for IBMP-8.3, 4,826 for IBMP-8.1, 7,882 for IBMP-8.2, and 25,000 for IBMP-8.4. A separate sera bank (851 samples) was employed to assess cross-reactivity with other tropical diseases. , a pathogen with high similarity to, showed cross-reactivity rates ranging from 0 to 2.17%. Inconclusive results were negligible (0 to 0.71%). Bland-Altman and Deming regression analysis based on 200 randomly selected CD-positive and negative samples demonstrated interchangeability with respect to CD diagnostic performance in both singleplex and multiplex assays. Our results suggested that these chimeras can potentially replace antigens currently used in commercially available assay kits. Moreover, the use of multiplex platforms, such as LMA assays employing 2 or more IBMP antigens, would abrogate the need for 2 different testing techniques when diagnosing CD.

show abstract

“…In contrast, a free-label biosensor that uses optical transducers needs fewer steps and a shorter assay time and still shows high sensitivity. An optical immunosensor (SPRCruzi) with a surface plasmon resonance (SPR) transducer was recently developed for CD diagnosis [83]. SPR sensors use surface plasmons, which are electromagnetic waves that can be excited by light at gold sensor interfaces, to transduce a biochemical interaction.…”

Section: Biosensorsmentioning

confidence: 99%

Chagas Disease Treatment Efficacy Biomarkers: Myths and Realities

2019

View full text Add to dashboard Cite

Chagas disease (CD), caused by Trypanosoma cruzi, affects millions of people worldwide. Although CD R&D has made progress during the last decade, clinicians and general practitioners are still facing the same challenge, i.e., the lack of adequate markers of clinical cure, hindering assessment of new drug efficacy in clinical trials and counseling of patients about treatment outcome. To date, no new markers have been validated as surrogates of seroreversion-the only marker of parasitological cure which is itself considered to be a surrogate of clinical benefit. T. cruzi DNA detected using PCR cannot currently be considered as a surrogate of seroconversion. Much emphasis has been placed on different T. cruzi antigens but no definite proof of correlation between titers, as determined by serology at a given timepoint, and seroreversion has been shown. Thanks to the improvement of analytical methods and the application of new methodologies, the identification of potential new markers is being facilitated, and some of these are progressing. However, there is a long journey from the identification of a potential biomarker to its clinical validation and acceptance by the regulatory authorities that requires a common effort from the entire Chagas community.

show abstract

Development and evaluation of a SPR-based immunosensor for detection of anti-Trypanosoma cruzi antibodies in human serum

Cited by 21 publications

References 31 publications

Biosensors to Diagnose Chagas Disease: A Brief Review

Biosensors to Diagnose Chagas Disease: A Brief Review

Performance Assessment of a Trypanosoma cruzi Chimeric Antigen in Multiplex Liquid Microarray Assays

Chagas Disease Treatment Efficacy Biomarkers: Myths and Realities

Contact Info

Product

Resources

About